MedTrace Logo

Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)

NCT03809377 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-03-27

No results posted yet for this study

Summary

Peripheral blood samples will be taken with informed consent from radiotherapy patients before and during treatment fractions for sarcoma, breast, lung, gut, genitourinary and head \& neck tumours at The Royal Marsden. Candidate genes identified by PHE, Columbia and/or in the literature as being specific to radiation responses will be assessed, together with genes relevant to systemic inflammatory and immune responses, to identify transcriptional responses for a range of doses and exposures on an inter-individual basis. Data will be analysed using existing and new statistical tools focused on count data modelling. The intended outcome is identification of a radiation specific panel of genes to inform individual radiation responses and if the results are favourable, a large scale follow up to this project is expected.

Conditions

Interventions

PROCEDURE

Blood donation during radiotherapy

Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy

Sponsors & Collaborators

  • Public Health England

    collaborator OTHER_GOV

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Navita Somaiah · The Institute of Cancer Research, London, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-09
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809377 on ClinicalTrials.gov